Income Statement Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.66 USD | -0.92% |
|
-0.82% | -1.87% |
| 01-22 | Leerink Partners Adjusts Edwards Lifesciences Price Target to $88 From $87, Maintains Market Perform Rating | MT |
| 01-22 | Venus Medtech Clarifies U.S. Patent Lawsuit Involving Subsidiary | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 4.39B | 5.23B | 5.38B | 6B | 5.44B | |||||
Total Revenues | 4.39B | 5.23B | 5.38B | 6B | 5.44B | |||||
Cost of Goods Sold, Total | 1.08B | 1.25B | 1.08B | 1.38B | 1.12B | |||||
Gross Profit | 3.31B | 3.98B | 4.3B | 4.62B | 4.32B | |||||
Selling General & Admin Expenses, Total | 1.23B | 1.49B | 1.57B | 1.82B | 1.79B | |||||
R&D Expenses | 761M | 903M | 945M | 1.07B | 1.05B | |||||
Other Operating Expenses | - | - | - | - | -300K | |||||
Other Operating Expenses, Total | 1.99B | 2.4B | 2.51B | 2.9B | 2.84B | |||||
Operating Income | 1.32B | 1.59B | 1.79B | 1.73B | 1.48B | |||||
Interest Expense, Total | -15.8M | -18.4M | -19.2M | -17.6M | -19.8M | |||||
Interest And Investment Income | 23.4M | 17.4M | 35.5M | 67.2M | 120M | |||||
Net Interest Expenses | 7.6M | -1M | 16.3M | 49.6M | 100M | |||||
Income (Loss) On Equity Invest. | 900K | 14.4M | 17.7M | - | - | |||||
Currency Exchange Gains (Loss) | 12.3M | 5M | -1.2M | 10.5M | 7.1M | |||||
Other Non Operating Income (Expenses) | -1M | 2.2M | - | 11.5M | 6.8M | |||||
EBT, Excl. Unusual Items | 1.34B | 1.61B | 1.82B | 1.8B | 1.6B | |||||
Restructuring Charges | - | - | -62.3M | - | -61M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | -300K | -8.6M | -18.8M | -8.8M | 54.4M | |||||
Asset Writedown | - | - | - | - | - | |||||
In Process R&D Expenses | - | - | - | - | - | |||||
Insurance Settlements | - | - | 3.8M | - | - | |||||
Legal Settlements | -405M | -20.6M | -15.8M | -204M | -40.4M | |||||
Other Unusual Items | -13.6M | 124M | 35.8M | 9M | - | |||||
EBT, Incl. Unusual Items | 917M | 1.7B | 1.77B | 1.6B | 1.55B | |||||
Income Tax Expense | 93.3M | 199M | 246M | 199M | 152M | |||||
Earnings From Continuing Operations | 823M | 1.5B | 1.52B | 1.4B | 1.4B | |||||
Earnings Of Discontinued Operations | - | - | - | - | 2.77B | |||||
Net Income to Company | 823M | 1.5B | 1.52B | 1.4B | 4.17B | |||||
Minority Interest | - | - | - | 3M | 4.9M | |||||
Net Income - (IS) | 823M | 1.5B | 1.52B | 1.4B | 4.17B | |||||
Net Income to Common Incl Extra Items | 823M | 1.5B | 1.52B | 1.4B | 4.17B | |||||
Net Income to Common Excl. Extra Items | 823M | 1.5B | 1.52B | 1.4B | 1.4B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 1.32 | 2.41 | 2.46 | 2.31 | 6.98 | |||||
Basic EPS - Continuing Operations | 1.32 | 2.41 | 2.46 | 2.31 | 2.34 | |||||
Basic Weighted Average Shares Outstanding | 623M | 623M | 619M | 607M | 598M | |||||
Net EPS - Diluted | 1.3 | 2.38 | 2.44 | 2.3 | 6.97 | |||||
Diluted EPS - Continuing Operations | 1.3 | 2.38 | 2.44 | 2.3 | 2.34 | |||||
Diluted Weighted Average Shares Outstanding | 632M | 631M | 624M | 609M | 599M | |||||
Normalized Basic EPS | 1.34 | 1.61 | 1.84 | 1.86 | 1.68 | |||||
Normalized Diluted EPS | 1.32 | 1.59 | 1.83 | 1.85 | 1.67 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 1.42B | 1.72B | 1.93B | 1.87B | 1.64B | |||||
EBITA | 1.32B | 1.59B | 1.8B | 1.74B | 1.49B | |||||
EBIT | 1.32B | 1.59B | 1.79B | 1.73B | 1.48B | |||||
EBITDAR | 1.45B | 1.75B | 1.96B | 1.9B | 1.66B | |||||
Effective Tax Rate - (Ratio) | 10.18 | 11.69 | 13.89 | 12.43 | 9.82 | |||||
Total Current Taxes | 146M | 243M | 496M | 461M | 315M | |||||
Total Deferred Taxes | -52.2M | -44M | -251M | -262M | -163M | |||||
Normalized Net Income | 835M | 1B | 1.14B | 1.13B | 1B | |||||
Interest on Long-Term Debt | 15.8M | 18.4M | 19.2M | 17.6M | 19.8M | |||||
Non-Cash Pension Expense | 400K | 300K | -1.1M | -1.2M | -600K | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 761M | 903M | 973M | 1.07B | 1.05B | |||||
Net Rental Expense, Total | 30.5M | 29.7M | 28.8M | 30.1M | 28.1M | |||||
Imputed Operating Lease Interest Expense | 5.61M | 6.31M | 6.4M | 6.11M | 6.43M | |||||
Imputed Operating Lease Depreciation | 24.89M | 23.39M | 22.4M | 23.99M | 21.67M | |||||
Maintenance & Repair Expenses, Total | - | - | - | - | - | |||||
Stock-Based Comp., COGS (Total) | 17.2M | 20.4M | 22.8M | 23.6M | 26.7M | |||||
Stock-Based Comp., R&D Exp. (Total) | 18.8M | 23.3M | 28.7M | 33.4M | 36.4M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 56.6M | 65.6M | 75.3M | 82.4M | 82.5M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | 16.7M | |||||
Total Stock-Based Compensation | 92.6M | 109M | 127M | 139M | 162M |
- Stock Market
- Equities
- EW Stock
- Financials Edwards Lifesciences Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















